The JAG1 Knockout KYSE-30 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the JAG1 gene in the human KYSE-30 esophageal squamous cell carcinoma line. This product provides a heterogeneous loss-of-function model for the Jagged1 protein, a critical ligand in the Notch signaling pathway. The polyclonal nature ensures representation of diverse genetic modifications, making it suitable for studying JAG1-dependent cellular processes without clonal selection biases. This cell model is an essential tool for probing Notch-mediated cell-cell communication in epithelial cancer biology.
The KYSE-30 cell line originates from a moderately differentiated human esophageal squamous cell carcinoma, retaining epithelial characteristics and serving as a well-established in vitro model for esophageal cancer research. These cells exhibit robust proliferative and migratory properties, along with an active Notch signaling axis. The derivation from a clinical tumor context enables the investigation of JAG1 function in a disease-relevant setting, reflecting the molecular aberrations commonly observed in squamous cell carcinomas of the esophagus.
JAG1 encodes Jagged1, a transmembrane ligand for Notch receptors NOTCH1 and NOTCH3. Upon engagement, sequential cleavage by ADAM17 and gamma-secretase releases NICD, which translocates to the nucleus and complexes with CSL to activate transcription of HES1, HEY1, MYC, and CCND1. Expression of JAG1 is regulated by NF-??B, ETS1, TGF-??, and hypoxia-inducible factors. The E3 ligase MIB1 ubiquitinates Jagged1 to facilitate signaling. CRISPR/Cas9-mediated JAG1 disruption abolishes ligand-dependent Notch activation, reducing NICD levels and downregulating target gene expression, thereby affecting cell proliferation, survival, and differentiation.
In the KYSE-30 esophageal cancer context, JAG1 knockout provides a powerful tool to dissect the role of Jagged1-Notch signaling in tumorigenic processes. Esophageal squamous cell carcinoma commonly exhibits deregulated Notch pathway activity, which can influence epithelial-mesenchymal transition (EMT), angiogenesis, and resistance to apoptosis. By abolishing Jagged1 expression, this polyclonal knockout model enables researchers to investigate how loss of this ligand impacts cellular behaviors such as migration, invasion, and survival, and to assess potential compensatory mechanisms from other Notch ligands. It offers a physiologically relevant system for evaluating JAG1 as a therapeutic target.
This product is ideally suited for numerous experimental applications, including western blot detection of JAG1, NOTCH1, and cleaved NICD; RT-qPCR for HES1 and HEY1 expression; Boyden chamber migration and invasion assays; flow cytometry-based apoptosis analysis; Notch transcriptional reporter luciferase assays; co-immunoprecipitation of JAG1-Notch complexes; and transcriptomic profiling via RNA-seq. These polyclonal knockout cells enable functional genomics, drug target validation, and tumor microenvironment modeling. For ordering or technical support, contact Ascent Research.
